ABLi Therapeutics Announces Positive Phase 2 Results for Risvodetinib in Untreated Parkinson’s Disease

ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosin...

October 10, 2025 | Friday | News
Greenwich LifeSciences Expands Phase III FLAMINGO-01 Breast Cancer Trial to Austria

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...

October 10, 2025 | Friday | News
Neurona Therapeutics Treats First Non-MTS Subject in Phase 1/2 Trial of NRTX-1001 for Drug-Resistant Temporal Lobe Epilepsy

  - First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events re...

October 09, 2025 | Thursday | News
BBG Advanced Therapies and CELLforCURE Forge Transatlantic Partnership to Expand Global ATMP Manufacturing Capabilities

BBG Advanced Therapies (BBGAT), a subsidiary of BioBridge Global (San Antonio, TX USA), and  CELLforCURE, part of SEQENS Group (Les Ulis, France), are...

October 08, 2025 | Wednesday | News
Leo Cancer Care Partners with TibaRay to Power Next-Gen Upright Radiotherapy with Advanced Linac Technology

Leo Cancer Care announced that it has placed orders for TibaRay's advanced linear accelerators (linacs), which will be evaluated as an upgrade option to th...

October 06, 2025 | Monday | News
Sitryx Therapeutics Receives FDA Clearance to Advance SYX-5219 Into Phase 1b Trial for Atopic Dermatitis

SYX-5219 is a first-in-class oral PKM2 modulator designed to drive sustained disease remission across a range of autoimmune diseases Phase 1b trial to...

October 03, 2025 | Friday | News
Draig Therapeutics Secures FDA Clearance to Launch Phase 2 Trial of DT-101 for Major Depressive Disorder

DT-101 is designed to allow effective modulation of the AMPA receptor without compromising safety Phase 2 clinical trial initiation anticipated before...

October 03, 2025 | Friday | News
Igyxos Biotherapeutics Secures €5.7M France 2030 Grant to Advance Infertility Antibody Therapy

Igyxos Biotherapeutics, a biotechnology company dedicated to developing innovative monoclonal antibodies for infertility treatment, announced that it has...

October 03, 2025 | Friday | News
Galapagos Cell Therapy Division in Play: Board Eyes Binding Bids Within Weeks

Galapagos announced that its Board of Directors (the “Board”) had decided to explore all strategic alternatives for its cell therapy business...

October 02, 2025 | Thursday | News
Kynexis Doses First Patient in Phase 2 Trial of KYN-5356 for Cognitive Impairment Associated with Schizophrenia

Kynexis, a clinical-stage biotechnology company focused on precision therapeutics for brain diseases, announced that the first patient has been dosed in ...

October 01, 2025 | Wednesday | News
VERAXA Biotech and Secarna Pharmaceuticals Form Strategic Alliance to Develop Next-Generation Antibody Oligonucleotide Conjugates

VERAXA Biotech, an emerging leader in designing novel cancer therapies and proposed de-SPAC acquisition target of Voyager Acquisition Corp. (NASDAQ:VACH,...

October 01, 2025 | Wednesday | News
Harrow to Acquire Melt Pharmaceuticals, Advancing Non-Opioid, Needle-Free Sedation Therapy MELT-300

Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced that it has entered into an ag...

September 30, 2025 | Tuesday | News
ADvantage Therapeutics Secures $2.5M NIH Grant to Advance Alzheimer’s Candidate AD04®

ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, announced it has been awarded a $2.5 mil...

September 30, 2025 | Tuesday | News
Philips Unveils Next-Generation CT and Helium-Free MR Systems to Transform Precision and Sustainability in Radiation Therapy

New Rembra RT and Areta RT [1] CT platforms drive accuracy and efficiency in radiation therapy with advanced workflows and long-term value Philips deb...

September 29, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close